Manufacturing Pharma’s manufacturing reconfigurations provide CDMOs with expansion opportunities Pharmaceutical TechnologyManufacturing deals saw an unusual burst of recent activity, with a spike in the number of CDMOs acquiring facilities from pharma companies.Read full story pharminent May 12, 2026 (Last updated: May 16, 2026) Pharmaceutical Technology Manufacturing deals saw an unusual burst of recent activity, with a spike in the number of CDMOs acquiring facilities from pharma companies. Read full story Post navigation Previous: BridgeBio’s Attruby challenges Pfizer’s Vyndamax legacy in pivotal ATTR trialNext: FDA weighs drug repurposing pathway for underserved diseases Related Stories Manufacturing BMS banks on Texas for $2.3bn multi-modal manufacturing facility pharminent August 11, 2026 Manufacturing AsymBio to secure $184m to support growth in biologics manufacturing pharminent August 5, 2026 Manufacturing Lilly and Resilience invest $750M in diabetes and obesity drug device supply pharminent July 31, 2026
